CXCL10 and non-small cell lung carcinoma: In another study of 18 patients with stage III NSCLC receiving concurrent chemoradiotherapy, CR2 and IFNGR2 were identified as positive prognostic biomarkers and treatment-induced changes of CXCL10 and IL-10 as negative predictive biomarkers [21].